For the treatment of superficial transitional cell carcinoma (TCC) of the urinary bladder, regardless of antecedent intravecical treatment superficial TCC comprises the following: carcinoma in situ (CIS), papillary tumors limited to the mucosa (stage Ta), papillary tumors invoiving the lamina propria but not the muscle layer of the bladder (stage T1), or any combination thereof.
Immucyst is indicated for treatment and prophylaxis of primary or recurrent carcinoma insitu (CIS) of the urinary bladder and for prophylaxis following trans-urethral resection (TUR) of primary or rcurrent stage Ta and / or T1 papillary tumors.